Shell M&A Chief Exits After BP Takeover Proposal Rejected 
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease 
OpenAI Explores Massive Funding Round at $750 Billion Valuation 
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Amazon in Talks to Invest $10 Billion in OpenAI as AI Firm Eyes $1 Trillion IPO Valuation 
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track 
noyb Files GDPR Complaints Against TikTok, Grindr, and AppsFlyer Over Alleged Illegal Data Tracking. 
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change 
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness 
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy 
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims 
LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal 
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies 
WILMINGTON, Del., Sept. 01, 2016 -- Rigrodsky & Long, P.A.:
- Do you, or did you, own shares of Insmed Incorporated (NASDAQ:INSM)?
- Did you purchase your shares between March 18, 2013 and June 8, 2016, inclusive?
- Did you lose money in your investment?
Rigrodsky & Long, P.A. reminds shareholders of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ:INSM) of an upcoming deadline involving a securities fraud class action lawsuit commenced against the Company. A complaint was filed in the United States District Court for the District of New Jersey on behalf of all persons or entities that purchased the common stock of Insmed between March 18, 2013 and June 8, 2016, inclusive (the “Class Period”), alleging violations of the Securities Exchange Act of 1934 against the Company and certain of its officers (the “Complaint”).
The Complaint alleges that throughout the Class Period, defendants made materially false and misleading statements, and omitted materially adverse facts, about the Company’s business, operations and prospects. Specifically, the Complaint alleges that the defendants concealed from the investing public that: (1) the data on which Insmed’s European marketing authorization application (“MAA”) for Arikayce, its lead product candidate, relied was not likely to support approval by the European Medicines Agency (“EMA”) for the treatment of NTM lung disease; (2) Arikayce’s approval by the EMA for the treatment of NTM lung disease and subsequent commercialization in Europe were thus less likely and/or imminent than Insmed had led investors to believe; and (3) as a result of the foregoing, Insmed’s public statements were materially false and misleading at all relevant times. As a result of defendants’ alleged false and misleading statements, the Company’s stock traded at artificially inflated prices during the Class Period.
If you wish to serve as lead plaintiff, you must move the Court no later than September 13, 2016. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Any member of the proposed class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.
If you purchased shares of Insmed during the Class Period, or purchased shares prior to the Class Period and still hold Insmed, and wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact Timothy J. MacFall, Esquire or Peter Allocco of Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803 at (888) 969-4242; by e-mail to [email protected]; or at: http://rigrodskylong.com/investigations/insmed-incorporated-insm.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Timothy J. MacFall, Esquire Peter Allocco (888) 969-4242 (516) 683-3516 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
